Early trial of experimental cancer combo halted after just 6 patients
NCT ID NCT06870487
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after enrolling only 6 participants. Because it was stopped, we have very limited information on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-08046032 (a new drug given by IV) and sasanlimab (an immunotherapy given as a shot)
- What this could lead to
- If it works, this could point toward a new treatment option for certain advanced cancers that have not responded to standard therapies.
- What could go wrong
- This was a very early Phase 1 trial with only 6 participants and was terminated early, so results are limited. The drug may not prove safe or effective in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutchinson Cancer Center.
Seattle, Washington, 98109, United States
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
University of Washington Medical Center- Montlake
Seattle, Washington, 98195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can an immune booster outsmart brain lymphoma?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?